Previous 10 | Next 10 |
2023-04-11 08:58:33 ET Ironwood Pharmaceuticals ( NASDAQ: IRWD ) said on Tuesday that COO Jason Rickard's last day in the company will be May 12. The company is set to eliminate the role of COO, and Rickard's responsibilities will be transferred to the other members ...
2023-03-16 06:31:14 ET Summary The pharma/biotech subsector is undervalued by 16% relative to 11-year averages. Healthcare equipment is the less attractive subsector regarding both valuation and quality. Fast facts on PBE, a biotechnology and genomics ETF. 10 stocks cheape...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that management will participate in the following investor conferences: Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 9:10 a.m. ET at the Boston Marriott Copley Place ...
Summary Pharmaceuticals and biotechnology still look attractive. Healthcare providers are close to their baseline in both valuation and quality. I look at iShares Genomics Immunology and Healthcare ETF, an ETF in genomics and immunology. 10 stocks cheaper than their peers in Nov...
Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2022 Earnings Conference Call February 16, 2023, 08:30 ET Company Participants Matt Roache - Director, IR Thomas McCourt - CEO & Director Michael Shetzline - Chief Medical Officer, SVP and Head, Research & Drug Developme...
The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Ironwood Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call Presentation
Ironwood Pharmaceuticals press release ( NASDAQ: IRWD ): Q4 Non-GAAP EPS of $0.27 beats by $0.01 . Revenue of $107.2M (-8.5% Y/Y) misses by $1.02M . For FY23, expected revenue is $420 to $435 million, vs. consensus of $426.65M. U.S. LINZESS Net Sales Growth of...
– 2022 GAAP and non-GAAP net income of $175 million – – 2022 adjusted EBITDA of $252 million; ended 2022 with $656 million in cash and cash equivalents – – FDA granted priority review to the sNDA for LINZESS® (linaclotide) for the treatm...
The U.S. Food and Drug Administration (FDA) granted priority review to AbbVie ( NYSE: ABBV ) and Ironwood Pharmaceuticals' ( NASDAQ: IRWD ) application seeking expanded approval of Linzess (linaclotide) to treat children and adolescents aged six years to 17 years with functio...
– FDA assigns 2 nd Quarter 2023 target action date – – If approved, LINZESS would be the first and only FDA-approved prescription therapy for functional constipation in this patient population – – Functional constipation affects an estimated ...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 8, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...